Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6 on the page. This represents a minor publication metadata update and does not modify study content or functionality.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4. This appears to be a minor version update to the page rather than a change to study information or functionality.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page now shows a new site revision label: Revision: v3.6.4, replacing the previous Revision: v3.6.3. This indicates an internal platform update rather than changes to the study information.SummaryDifference0.0%

- Check71 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3 to reflect the latest page version. This indicates an incremental update to the page's version metadata rather than a content change.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision label updated from v3.6.0 to v3.6.2. This indicates a newer build of the page and does not change the study content.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page now indicates that no participants are being recruited ('No longer looking for participants'). New navigation/help items were added (How to Read a Study Record, Common Questions, How to Join a Study), the Intervention/Treatment header formatting was adjusted, and the revision version was updated to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.